Search Result

Isoforms Recommended:	SGLT1

Results for "

SGLT1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	SGLT (33) Dipeptidyl Peptidase (3) Drug Derivative (1) Endogenous Metabolite (2) GLP Receptor (1) GLUT (3) HIV (2) Isotope-Labeled Compounds (1) Reference Standards (5) Small Interfering RNA (siRNA) (3) TNF Receptor (2)
By Research Areas:	Cancer (2) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (2) Metabolic Disease (30) Neurological Disease (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: SGLT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0142

Phloretin Maximum Cited Publications 24 Publications Verification NSC 407292; RJC 02792	SGLT Endogenous Metabolite GLUT	Metabolic Disease Cancer
Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill.，has anti-inflammatory activities. Phloridzin is a specific，competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC₅₀values of 49 μM and 61 μM，respectively ^[1].Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation .

HY-17638

Mizagliflozin 5 Publications Verification DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base	SGLT	Metabolic Disease
Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective *SGLT1* inhibitor, with a K_i of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation ^[1].

HY-14894

Ipragliflozin 5+ Cited Publications ASP1941	SGLT	Metabolic Disease
Ipragliflozin (ASP1941) is an orally active and selective *SGLT2* inhibitor with IC₅₀s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent ^[1].

HY-10449

Luseogliflozin TS 071	SGLT	Metabolic Disease
Luseogliflozin (TS 071) is a potent, selective, orally active *sodium-dependent glucose cotransporter (SGLT) 2* inhibitor, with an IC₅₀ of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC₅₀, 3990 nM). Luseogliflozin has the protential for researching type 2 diabetes ^[1] .

HY-123011

Henagliflozin SHR3824	SGLT	Metabolic Disease
Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC₅₀ values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research ^[1].

HY-N4100

Trilobatin 5+ Cited Publications	TNF Receptor HIV SGLT	Infection
Trilobatin, a natural sweetener derived from Lithocarpus polystachyus Rehd ^[1], Trilobatin is an *HIV-1* entry inhibitor targeting the HIV-1 Gp41 envelope . Neuroprotective effects ^[1]. Trilobatin is also a SGLT1/2 inhibitor that selectively induces the proliferation of human hepatoblastoma cells .

HY-123797

KGA-2727 2 Publications Verification	SGLT	Metabolic Disease
KGA-2727 is a first selective, high-affinity and orally active *SGLT1* inhibitor with K_is of 97.4 nM and 43.5 nM for human and rat SGLT1, respectively. The selectivity ratios (K_i for SGLT2/K_i for *SGLT1*) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 has antidiabetic efficacy ^[1].

HY-14894A

Ipragliflozin L-Proline 5+ Cited Publications	SGLT	Metabolic Disease
Ipragliflozin (L-Proline) is a highly potent and selective *SGLT2* inhibitor with an IC₅₀ of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.

HY-I1120

SGLT2-IN-1	SGLT	Metabolic Disease
SGLT2-IN-1 (Compound 5) is an inhibitor for sodium-dependent glucose cotransporter (SGLT2), with IC₅₀ of 33 nM in CHO cells transfected with human SGLT2. SGLT2-IN-1 is selective for SGLT2 over SGLT1. SGLT2-IN-1 is an active metabolite of dapagliflozinactive metabolite of dapagliflozin ^[1] .

HY-101122

LX2761	SGLT GLP Receptor	Metabolic Disease
LX2761 is an orally active, dual *SGLT1/SGLT2* inhibitor with IC₅₀ values of 2.2 nM and 2.7 nM against human *SGLT1* and *SGLT2, respectively. LX2761 locks human SGLT1* in an outward-open conformation and blocks its putative water permeation pathway. After oral administration, LX2761 is confined exclusively to the intestinal lumen, delays intestinal glucose absorption, regulates intestinal glucose metabolism, increases cecal glucose levels, reduces cecal pH, improves glycemic control and elevates plasma total *GLP-1* levels. However, LX2761 induces diarrhea in a dose-dependent manner. LX2761 can be used in diabetes-related research ^[1] .

HY-106158

T-1095	SGLT	Metabolic Disease
T-1095 is a selective and orally active Na ⁺-glucose cotransporter (SGLT) inhibitor with IC₅₀s of 22.8 µM and 2.3 µM for human SGLT1 and SGLT2, respectively. T-1095 can be used for diabetes research ^[1].

HY-109092

Licogliflozin 1 Publications Verification LIK066	SGLT	Metabolic Disease Inflammation/Immunology
Licogliflozin is a sodium glucose cotransporter (SGLT1 and *SGLT2*) inhibitor.

HY-138944

SGLT1/2-IN-1	SGLT	Metabolic Disease
SGLT1/2-IN-1 is a dual SGLT1/SGLT2 inhibitor extract from WO2015032272A1, compound 2 ^[1].

HY-N0142R

Phloretin (Standard) Maximum Cited Publications 24 Publications Verification NSC 407292 (Standard); RJC 02792 (Standard)	Reference Standards SGLT Endogenous Metabolite GLUT	Metabolic Disease Cancer
Phloretin (Standard) is the analytical standard of Phloretin. This product is intended for research and analytical applications. Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill., has anti-inflammatory activities. Phloridzin is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC₅₀values of 49 μM and 61 μM, respectively ^[1].Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation .

HY-169821

SGLT1/2-IN-8	SGLT	Metabolic Disease
SGLT1/2-IN-8 (compound 8) is a potent and orally active *SGLT1/2* dual inhibitor with IC₅₀ values of 4 nM and 1 nM, respectively. SGLT1/2-IN-8 exhibits anti-hyperglycemic effects and can be utilized in relevant research ^[1].

HY-145357

SGLT1/2-IN-2	SGLT	Metabolic Disease
SGLT1/2-IN-2 demonstrates potent dual inhibitory activities (IC₅₀ = 96 nM for SGLT1 and IC₅₀ = 1.3 nM for SGLT2).

HY-150322

SAR-7226	SGLT	Metabolic Disease
SAR-7226 is a *SGLT1* and *SGLT2* dual inhibitor. SAR-7226 can be used for research of type 2 diabetes ^[1].

HY-RS13280

SLC5A1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
SLC5A1 Human Pre-designed siRNA Set A contains three designed siRNAs for SLC5A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SLC5A1 Human Pre-designed siRNA Set A SLC5A1 Human Pre-designed siRNA Set A

HY-114308

SGL5213	SGLT	Metabolic Disease
SGL5213 is a potent, oral active and low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor, with IC₅₀ values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively. SGL5213 has potential to treat type 2 diabetes treatment ^[1].

HY-N4100R

Trilobatin (Standard)	TNF Receptor Reference Standards HIV SGLT	Infection
Trilobatin (Standard) is the analytical standard of Trilobatin. This product is intended for research and analytical applications. Trilobatin, a natural sweetener derived from?Lithocarpus polystachyus?Rehd ^[1], Trilobatin?is an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope . Neuroprotective effects ^[1]. Trilobatin is also a SGLT1/2 inhibitor that selectively induces the proliferation of human hepatoblastoma cells .

HY-124664

TP0438836	SGLT	Metabolic Disease
TP0438836 (compound 30b) is a *SGLT1* inhibitor, with IC₅₀ values of 28 nM and 7 nM for hSGLT1 and hSGLT2, respectively. TP0438836 can be used in diabetes research ^[1].

HY-14894R

Ipragliflozin (Standard) ASP1941 (Standard)	Reference Standards SGLT	Metabolic Disease
Ipragliflozin (Standard) is the analytical standard of Ipragliflozin. This product is intended for research and analytical applications. Ipragliflozin (ASP1941) is an orally active and selective *SGLT2* inhibitor with IC₅₀s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent ^[1].

HY-14894S2

Pragliflozin-13C6 ASP1941-¹³C₆	Isotope-Labeled Compounds SGLT	Metabolic Disease
Pragliflozin- ¹³C₆ (ASP1941- ¹³C₆) is ¹³C labeled Ipragliflozin. Ipragliflozin (ASP1941) is an orally active and selective *SGLT2* inhibitor with IC₅₀s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent ^[1] .

HY-109092A

rel-Licogliflozin rel-LIK066	SGLT	Metabolic Disease Inflammation/Immunology
rel-Licogliflozin is a relative configuration of Licogliflozin (HY-109092). Licogliflozin is a sodium glucose cotransporter (SGLT1 and *SGLT2*) inhibitor ^[1].

HY-122473

fluoro-Dapagliflozin	SGLT	Metabolic Disease
fluoro-Dapagliflozin, a structural analog of Dapagliflozin, is a selective *SGLT2* inhibitor with K_i values of 5.3 nM and 330 nM for SGLT2 and SGLT1, respectively. fluoro-Dapagliflozin blocks glucose transport and glucose-coupled currents ^[1].

HY-I1120R

SGLT2-IN-1 (Standard)	Reference Standards SGLT	Metabolic Disease
SGLT2-IN-1 (standard) is the analytical standard for SGLT2-IN-1. This product is used for research and analytical applications. SGLT2-IN-1 (Compound 5) is an inhibitor for sodium-dependent glucose cotransporter (SGLT2), with IC₅₀ of 33 nM in CHO cells transfected with human SGLT2. SGLT2-IN-1 is selective for SGLT2 over SGLT1. SGLT2-IN-1 is an active metabolite of dapagliflozinactive metabolite of dapagliflozin.

HY-17638A

Mizagliflozin (sebacate) DSP-3235 (sebacate); KGA-3235 (sebacate); GSK-1614235 (sebacate)	SGLT	Neurological Disease
Mizagliflozin sebacate (DSP-3235 sebacate) is a sodium-glucose cotransporter inhibitor with activity in improving vascular cognitive impairment caused by small vessel disease. Mizagliflozin sebacate improves blood flow and reverses vascular cognitive impairment by inhibiting neuronal SGLT1 activity. Mizagliflozin sebacate also showed the ability to increase the survival rate of IL-1β-treated PC12HS cells. Mizagliflozin sebacate promotes improvements in spatial learning and memory caused by small vessel disease in mouse models ^[1].

HY-186207

Demethyl-LX2761	SGLT	Metabolic Disease
Demethyl-LX2761 is a selective sodium-glucose cotransporter 1 (SGLT1) inhibitor. Demethyl-LX2761 can be used for the research of type 2 diabetes ^[1].

HY-178734

Janagliflozin	SGLT	Metabolic Disease
Janagliflozin is orally active and highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC₅₀=0.0058 μM for SGLT2 and 4.802 μM for SGLT1). Janagliflozin inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion (UGE) to lower blood glucose levels. Janagliflozin is promising for research of type 2 diabetes mellitus ^[1] .

HY-RS13281

Slc5a1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Slc5a1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Slc5a1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Slc5a1 Mouse Pre-designed siRNA Set A Slc5a1 Mouse Pre-designed siRNA Set A

HY-RS13282

Slc5a1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Slc5a1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Slc5a1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Slc5a1 Rat Pre-designed siRNA Set A Slc5a1 Rat Pre-designed siRNA Set A

HY-180527

SGLT2-IN-5	SGLT Dipeptidyl Peptidase	Metabolic Disease
SGLT2-IN-5 (Compound 99) is an orally active *SGLT2* inhibitor with IC₅₀ values for *SGLT2, SGLT1, and DPP4* of 0.8, 23, and 58 nM respectively. SGLT2-IN-5 controls blood sugar levels in diabetic rat models and increases the levels of active GLP-1. SGLT2-IN-5 can be used for the study of type 2 diabetes ^[1].

HY-17604

Bexagliflozin 1 Publications Verification EGT1442; EGT0001442; THR-1442	SGLT	Cardiovascular Disease Metabolic Disease
Bexagliflozin (EGT1442) is an orally active and selective *SGLT2* inhibitor with IC₅₀ values of 0.002 μM and 5.6 μM for SGLT2 and SGLT1, respectively. Bexagliflozin selectively inhibits *SGLT2*-mediated sodium-dependent glucose uptake. Bexagliflozin induces saturable urinary glucose excretion in normal rats and dogs. Bexagliflozin reduces blood glucose and HbA_1c levels in db/db mice without affecting body mass or insulin level. Bexagliflozin can be used for the research of type 2 diabetes mellitus, hypertensive stroke ^[1].

HY-10449R

Luseogliflozin (Standard) TS 071 (Standard)	Reference Standards SGLT	Metabolic Disease
Luseogliflozin (Standard) is the analytical standard of Luseogliflozin (HY-10449). This product is intended for research and analytical applications. Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC₅₀ of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC₅₀, 3990 nM). Luseogliflozin has the protential for researching type 2 diabetes ^[1] .

HY-180528

SGLT2-IN-6	SGLT Dipeptidyl Peptidase	Metabolic Disease
SGLT2-IN-6 (Compound 101) is an orally active *SGLT2* inhibitor with IC₅₀ values for *SGLT2, SGLT1, and DPP4* of 0.8, 6.7, and 72 nM respectively. SGLT2-IN-6 controls blood sugar levels in diabetic rat models and increases the levels of active GLP-1. SGLT2-IN-6 can be used for the study of type 2 diabetes ^[1].

HY-180784

Hypoglycemic agent 4	Drug Derivative Dipeptidyl Peptidase SGLT GLUT	Metabolic Disease
Hypoglycemic agent 4 (Compound 5b) is a tetrahydroacridine derivative with orally active hypoglycemic activity. Hypoglycemic agent 4 has a good binding affinity for the key diabetic targets: DPP-IV, *SGLT1, and GLUT2*. Hypoglycemic agent 4 can inhibit glucose diffusion. Hypoglycemic agent 4 can reduce fasting blood sugar in Streptozotocin (HY-13753)-induced diabetic rats and its effect is comparable to Gliclazide (HY-B0753). Hypoglycemic agent 4 can be used for research of type 2 diabetes ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0142

Phloretin Maximum Cited Publications 24 Publications Verification NSC 407292; RJC 02792	Classification of Application Fields Rosaceae Plants Dihydrochalcones Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Microorganisms Malus pumila Mill. Phenols Polyphenols Disease Research Fields Source Classification Cancer	SGLT Endogenous Metabolite GLUT
Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill.，has anti-inflammatory activities. Phloridzin is a specific，competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC₅₀values of 49 μM and 61 μM，respectively ^[1].Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation .

HY-N4100

Trilobatin 5+ Cited Publications	Infection Quinones Flavonoids Classification of Application Fields Vernicia fordii (Hemsl.) Airy Shaw Plants Dihydrochalcones Fagaceae Naphthalene Quinones Disease Research Fields Sweeteners Food Research	TNF Receptor HIV SGLT
Trilobatin, a natural sweetener derived from Lithocarpus polystachyus Rehd ^[1], Trilobatin is an *HIV-1* entry inhibitor targeting the HIV-1 Gp41 envelope . Neuroprotective effects ^[1]. Trilobatin is also a SGLT1/2 inhibitor that selectively induces the proliferation of human hepatoblastoma cells .

HY-N0142R

Phloretin (Standard) Maximum Cited Publications 24 Publications Verification NSC 407292 (Standard); RJC 02792 (Standard)	Structural Classification Human Gut Microbiota Metabolites Flavonoids Classification of Application Fields Malus pumila Mill. Rosaceae Phenols Plants Endogenous metabolite Disease Research Fields Source Classification Cancer	Reference Standards SGLT Endogenous Metabolite GLUT
Phloretin (Standard) is the analytical standard of Phloretin. This product is intended for research and analytical applications. Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill., has anti-inflammatory activities. Phloridzin is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC₅₀values of 49 μM and 61 μM, respectively ^[1].Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation .

HY-N4100R

Trilobatin (Standard)	Quinones Structural Classification Flavonoids Vernicia fordii (Hemsl.) Airy Shaw Plants Dihydrochalcones Fagaceae Naphthalene Quinones	TNF Receptor Reference Standards HIV SGLT
Trilobatin (Standard) is the analytical standard of Trilobatin. This product is intended for research and analytical applications. Trilobatin, a natural sweetener derived from?Lithocarpus polystachyus?Rehd ^[1], Trilobatin?is an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope . Neuroprotective effects ^[1]. Trilobatin is also a SGLT1/2 inhibitor that selectively induces the proliferation of human hepatoblastoma cells .

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P703207

	SLC5A1 Protein, Human (HEK293, His) NAGT; SGLT1	Human	HEK293
	SLC5A1 Protein, Human (HEK293, His) is the recombinant human-derived SLC5A1, expressed by HEK293 , with His labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-14894S2

Pragliflozin-13C6
Pragliflozin- ¹³C₆ (ASP1941- ¹³C₆) is ¹³C labeled Ipragliflozin. Ipragliflozin (ASP1941) is an orally active and selective *SGLT2* inhibitor with IC₅₀s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent ^[1] .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks